2022
Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor
Jones DH, Bansal P, Bernstein JA, Fatteh S, Harper J, Hsu FI, O’Connor M, Park N, Suez D. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor. World Allergy Organization Journal 2022, 15: 100621. PMID: 35145604, PMCID: PMC8804245, DOI: 10.1016/j.waojou.2021.100621.Peer-Reviewed Original ResearchManagement of HAEMost patientsHereditary angioedemaC1 esterase inhibitorAngioedema attacksHAE attacksMedian ageClinical profileSerum levelsRhC1-INHTreatment outcomesRecombinant human C1 esterase inhibitorNormal C1 esterase inhibitorEsterase inhibitorHuman C1 esterase inhibitorAcute HAE attacksHigh-dose antihistaminesUS treatment centersPatient-reported assessmentsLow serum levelsPatient-reported outcomesC1-INH deficiencyAvailability of treatmentImproved disease controlBreakthrough attacks
2020
Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial
Levy DS, Farkas H, Riedl MA, Hsu FI, Brooks JP, Cicardi M, Feuersenger H, Pragst I, Reshef A. Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. Allergy, Asthma & Clinical Immunology 2020, 16: 8. PMID: 32042283, PMCID: PMC7001333, DOI: 10.1186/s13223-020-0409-3.Peer-Reviewed Original ResearchOpen-label extensionC1-INHHealthy babyFemale subjectsFirst trimesterSubgroup analysisHereditary angioedemaHAE-C1INHIU/Severe angioedema attacksSubcutaneous C1-INHPhase 3 trialParallel-arm trialAttacks/monthLong-term efficacyFemale sex hormonesPre-study periodSubgroup of subjectsHAE attacksRoutine prophylaxisEfficacy endpointEligible subjectsUneventful pregnancyAngioedema attacksSex hormones